NEW YORK, July 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2018 financial results prior to market open on Thursday, August 2, 2018. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.
Intercept management will also be presenting at the following upcoming investor conference:
- 2018 Wedbush PacGrow Healthcare Conference at 8:35 a.m. ET on Tuesday, August 14, 2018
Webcast information for these events will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept’s website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.
| CONTACT | |||
| For more information about Intercept, please contact: | |||
| Mark Vignola | |||
| +1-646-747-1000 | |||
| investors@interceptpharma.com | |||
| Media inquiries: media@interceptpharma.com | |||